title: Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
abstract: Thirty-three patients with disseminated malignant melanoma were entered in a phase II study of the new nitrosourea S 10036 using a 100-mg/m2 weekly induction schedule for 3-4 consecutive weeks. Patients who responded to this treatment were followed with a maintenance therapy every 3 weeks. Toxic effects were mainly hematological and consisted of delayed thrombocytopenia and leukopenia. Among 30 patients who could be evaluated, eight partial responses were observed (response rate, 26.67%); among seven patients with cerebral metastasis, two partial responses were observed. This multicentric study is currently being continued to confirm this interim report.
authors.affiliation: Service d'Oncologie Médicale, Hôpital La Pitié Salpêtrière, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Khayat
authors.forename: J P
authors.initials: JP
authors.lastname: Bizzari
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: H
authors.initials: H
authors.lastname: Naman
authors.forename: M
authors.initials: M
authors.lastname: Weil
authors.forename: A
authors.initials: A
authors.lastname: Goupil
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: J
authors.initials: J
authors.lastname: Rouesse
authors.forename: P
authors.initials: P
authors.lastname: Banzet
authors.forename: C
authors.initials: C
authors.lastname: Jacquillat
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine